[Bone marrow transplantation patients in the intensive care unit].
Der knochenmarktransplantierte Patient auf der Intensivstation.
Complications
Critical care
Hematopoietic stem cell transplantation
Mechanical ventilation
Sepsis
Journal
Medizinische Klinik, Intensivmedizin und Notfallmedizin
ISSN: 2193-6226
Titre abrégé: Med Klin Intensivmed Notfmed
Pays: Germany
ID NLM: 101575086
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
26
10
2020
accepted:
08
01
2021
revised:
20
11
2020
pubmed:
11
2
2021
medline:
11
3
2021
entrez:
10
2
2021
Statut:
ppublish
Résumé
Allogeneic hematopoetic stem cell transplantation yields improved long-term survival for patients with high-risk malignant and non-malignant hematologic disease. However, it is associated with high morbidity and mortality. A proportion of patients need intensive care due to infectious, immunological and/or toxic complications. The utility of intensive care unit (ICU) treatments as mechanical ventilation and renal replacement therapy for these patients is uncertain since mortality is high. We describe the most frequent complications and the treatment options concerning the ICU in recipients of allogeneic hematopoetic stem cells. Die allogene hämatopoetische Stammzelltransplantation (HSZT) stellt für viele Patienten mit maligner, aber auch nichtmaligner hämatologischer Grunderkrankung die einzige Chance auf Heilung dar. Dies gilt insbesondere für Patienten, die genetisch bedingt ein hohes Rezidivrisiko haben oder sich refraktär auf eine konventionelle Therapie zeigen. Durch die allogene HSZT eröffnet sich für diese Patienten eine Langzeitperspektive bei ansonsten infauster Prognose. Diese Therapieform ist jedoch mit einer nicht unerheblichen Morbidität und Mortalität assoziiert. Ein Teil der Patienten wird aufgrund von infektiösen, immunologischen und/oder toxischen Komplikationen intensivpflichtig. Nach wie vor ist unklar, ob Patienten in solchen klinischen Situationen von einer Intensivtherapie mit mechanischer Beatmung und Nierenersatztherapie profitieren, da die Mortalität der Betroffenen hoch ist. Diese Arbeit beschreibt die wichtigsten Komplikationen und mögliche Behandlungsstrategien von allogen blutstammzelltransplantierten Patienten auf der Intensivstation.
Autres résumés
Type: Publisher
(ger)
Die allogene hämatopoetische Stammzelltransplantation (HSZT) stellt für viele Patienten mit maligner, aber auch nichtmaligner hämatologischer Grunderkrankung die einzige Chance auf Heilung dar. Dies gilt insbesondere für Patienten, die genetisch bedingt ein hohes Rezidivrisiko haben oder sich refraktär auf eine konventionelle Therapie zeigen. Durch die allogene HSZT eröffnet sich für diese Patienten eine Langzeitperspektive bei ansonsten infauster Prognose. Diese Therapieform ist jedoch mit einer nicht unerheblichen Morbidität und Mortalität assoziiert. Ein Teil der Patienten wird aufgrund von infektiösen, immunologischen und/oder toxischen Komplikationen intensivpflichtig. Nach wie vor ist unklar, ob Patienten in solchen klinischen Situationen von einer Intensivtherapie mit mechanischer Beatmung und Nierenersatztherapie profitieren, da die Mortalität der Betroffenen hoch ist. Diese Arbeit beschreibt die wichtigsten Komplikationen und mögliche Behandlungsstrategien von allogen blutstammzelltransplantierten Patienten auf der Intensivstation.
Identifiants
pubmed: 33564899
doi: 10.1007/s00063-021-00782-8
pii: 10.1007/s00063-021-00782-8
pmc: PMC7871956
doi:
Types de publication
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
111-120Références
Aarts MJ, Peters FP, Mandigers CM et al (2013) Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia. J Clin Oncol 31:4290–4296
pubmed: 23630211
Arendrup MC, Bille J, Dannaoui E et al (2012) ECIL‑3 classical diagnostic procedures for the diagnosis of invasive fungal diseases in patients with leukaemia. Bone Marrow Transplant 47:1030–1045
pubmed: 22231461
Azoulay E, Afessa B (2006) The intensive care support of patients with malignancy: do everything that can be done. Intensive Care Med 32:3–5
pubmed: 16308682
Azoulay E, Schlemmer B (2006) Diagnostic strategy in cancer patients with acute respiratory failure. Intensive Care Med 32:808–822
pubmed: 16715324
Azoulay E, Mokart D, Pene F et al (2013) Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium—a groupe de recherche respiratoire en reanimation onco-hematologique study. J Clin Oncol 31:2810–2818
pubmed: 23752112
Bayraktar UD, Shpall EJ, Liu P et al (2013) Hematopoietic cell transplantation-specific comorbidity index predicts inpatient mortality and survival in patients who received allogeneic transplantation admitted to the intensive care unit. J Clin Oncol 31:4207–4214
pubmed: 24127454
pmcid: 4878009
Bossaer JB, Hall PD, Garrett-Mayer E (2010) Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE. Support Care Cancer 19:231–237
pubmed: 20069435
Boyiadzis M, Arora M, Klein JP et al (2015) Impact of chronic graft-versus-host disease on late relapse and survival on 7,489 patients after myeloablative allogeneic hematopoietic cell transplantation for leukemia. Clin Cancer Res 21:2020–2028
pubmed: 25348512
Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383
pubmed: 3558716
Depuydt P, Kerre T, Noens L et al (2011) Outcome in critically ill patients with allogeneic BM or peripheral haematopoietic SCT: a single-centre experience. Bone Marrow Transplant 46:1186–1191
pubmed: 21042315
Fraccaroli A, Prevalsek D, Fritsch S et al (2018) Sequential HLA-haploidentical transplantation utilizing post-transplantation cyclophosphamide for GvHD prophylaxis in high-risk and relapsed/refractory AML/MDS. Am J Hematol 93:1524–1531
pubmed: 30194866
Gordin A, Netzer A, Joachims HZ et al (2005) Percutaneous tracheotomy in bone marrow transplant patients with severe thrombocytopenia. Otolaryngol Head Neck Surg 133:377–380
pubmed: 16143185
Heinicke T, Labopin M, Schmid C et al (2018) Reduced relapse incidence with FLAMSA-RIC compared with busulfan/fludarabine for acute myelogenous leukemia patients in first or second complete remission: a study from the acute leukemia working party of the European society for blood and marrow transplantation. Biol Blood Marrow Transplant 24:2224–2232
pubmed: 30009981
Jackson SR, Tweeddale MG, Barnett MJ et al (1998) Admission of bone marrow transplant recipients to the intensive care unit: outcome, survival and prognostic factors. Bone Marrow Transplant 21:697–704
pubmed: 9578310
Jenssen C, Brkljacic B, Hocke M et al (2016) EFSUMB guidelines on interventional ultrasound (INVUS), part VI—ultrasound-guided vascular interventions. Ultraschall Med 37:473–476
pubmed: 26515965
Khoury HJ, Wang T, Hemmer MT et al (2017) Improved survival after acute graft-versus-host disease diagnosis in the modern era. Haematologica 102:958–966
pubmed: 28302712
pmcid: 5477615
Kiehl MG, Kraut L, Schwerdtfeger R et al (2004) Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol 22:2816–2825
pubmed: 15254049
Kochanek M, Schalk E, von Bergwelt-Baildon M et al (2019) Management of sepsis in neutropenic cancer patients: 2018 guidelines from the infectious diseases working party (AGIHO) and intensive care working party (iCHOP) of the German society of hematology and medical oncology (DGHO). Ann Hematol 98:1051–1069
pubmed: 30796468
pmcid: 6469653
Legrand M, Max A, Peigne V et al (2012) Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med 40:43–49
pubmed: 21926615
Lengline E, Chevret S, Moreau AS et al (2015) Changes in intensive care for allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 50:840–845
pubmed: 25798675
Lusebrink E, Stark K, Bertlich M et al (2019) Safety of percutaneous dilatational tracheotomy in patients on dual antiplatelet therapy and anticoagulation. Crit Care Explor 1:e50
pubmed: 32166231
pmcid: 7063886
Majhail NS, Mau LW, Chitphakdithai P et al (2020) Transplant center characteristics and survival after allogeneic hematopoietic cell transplantation in adults. Bone Marrow Transplant 55:906–917
pubmed: 31740767
Mayer S, Pastores SM, Riedel E et al (2017) Short- and long-term outcomes of adult allogeneic hematopoietic stem cell transplant patients admitted to the intensive care unit in the peritransplant period. Leuk Lymphoma 58:382–390
pubmed: 27347608
Moosmann A, Bigalke I, Tischer J et al (2010) Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 115:2960–2970
pubmed: 20103780
Pene F, Aubron C, Azoulay E et al (2006) Outcome of critically ill allogeneic hematopoietic stem-cell transplantation recipients: a reappraisal of indications for organ failure supports. J Clin Oncol 24:643–649
pubmed: 16380411
Probst L, Schalk E, Liebregts T et al (2019) Prognostic accuracy of SOFA, qSOFA and SIRS criteria in hematological cancer patients: a retrospective multicenter study. J Intensive Care 7:41
pubmed: 31410290
pmcid: 6686367
Rhodes A, Evans LE, Alhazzani W et al (2017) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 43:304–377
pubmed: 28101605
Rowe JM, Ciobanu N, Ascensao J et al (1994) Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation. A report from the eastern cooperative oncology group (ECOG). Ann Intern Med 120:143–158
pubmed: 8256974
Rubenfeld GD, Crawford SW (1996) Withdrawing life support from mechanically ventilated recipients of bone marrow transplants: a case for evidence-based guidelines. Ann Intern Med 125:625–633
pubmed: 8849146
Saillard C, Blaise D, Mokart D (2016) Critically ill allogeneic hematopoietic stem cell transplantation patients in the intensive care unit: reappraisal of actual prognosis. Bone Marrow Transplant 51:1050–1061
pubmed: 27042832
Saria MG, Gosselin-Acomb TK (2007) Hematopoietic stem cell transplantation: implications for critical care nurses. Clin J Oncol Nurs 11:53–63
pubmed: 17441397
Schellongowski P, Kiehl M, Kochanek M et al (2016) Intensive care for cancer patients: an interdisciplinary challenge for cancer specialists and intensive care physicians. Memo 9:39–44
pubmed: 27069513
pmcid: 4786590
Schnell D, Legoff J, Mariotte E et al (2012) Molecular detection of respiratory viruses in immunocopromised ICU patients: incidence and meaning. Respir Med 106:1184–1191
pubmed: 22647492
pmcid: 7126300
Simon N, Coiteux V, Bruno B et al (2017) Dose adaptation of the drugs used for hematopoietic stem-cell transplantation in patients with comorbidity: obesity, chronic renal disease or hepatopathy: guidelines from the francophone society of bone marrow transplantation and cellular therapy (SFGM-TC). Bull Cancer 104:S99–S105
pubmed: 29173979
Singer M, Deutschman CS, Seymour CW et al (2016) The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 315:801–810
pubmed: 26903338
pmcid: 4968574
Soubani AO, Miller KB, Hassoun PM (1996) Pulmonary complications of bone marrow transplantation. Chest 109:1066–1077
pubmed: 8635332
Soubani AO, Kseibi E, Bander JJ et al (2004) Outcome and prognostic factors of hematopoietic stem cell transplantation recipients admitted to a medical ICU. Chest 126:1604–1611
pubmed: 15539734
Stecher SS, Beyer G, Goni E et al (2018) Extracorporeal membrane oxygenation in predominantly Leuco- and thrombocytopenic haematologic/oncologic patients with acute respiratory distress syndrome—a single-centre experience. Oncol Res Treat 41:539–543
pubmed: 30114706
Thiery G, Azoulay E, Darmon M et al (2005) Outcome of cancer patients considered for intensive care unit admission: a hospital-wide prospective study. J Clin Oncol 23:4406–4413
pubmed: 15994150
Tischer J, Stemmler HJ, Engel N et al (2013) Feasibility of clofarabine cytoreduction followed by haploidentical hematopoietic stem cell transplantation in patients with relapsed or refractory advanced acute leukemia. Ann Hematol 92:1379–1388
pubmed: 23928857
Tischer J, Engel N, Fritsch S et al (2015) Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings. Ann Hematol 94:1677–1688
pubmed: 26055139
Townsend WM, Holroyd A, Pearce R et al (2013) Improved intensive care unit survival for critically ill allogeneic haematopoietic stem cell transplant recipients following reduced intensity conditioning. Br J Haematol 161:578–586
pubmed: 23496350
pmcid: 4296346
Wohlfarth P, Beutel G, Lebiedz P et al (2017) Characteristics and outcome of patients after allogeneic hematopoietic stem cell transplantation treated with extracorporeal membrane oxygenation for acute respiratory distress syndrome. Crit Care Med 45:e500–e507
pubmed: 28410318
Wohlfarth P, Turki AT, Steinmann J et al (2018) Microbiologic diagnostic workup of acute respiratory failure with pulmonary infiltrates after allogeneic hematopoietic stem cell transplantation: findings in the era of molecular- and biomarker-based assays. Biol Blood Marrow Transplant 24:1707–1714
pubmed: 29550627
pmcid: 7110883
Yadav H, Nolan ME, Bohman JK et al (2016) Epidemiology of acute respiratory distress syndrome following hematopoietic stem cell transplantation. Crit Care Med 44:1082–1090
pubmed: 26807683
pmcid: 4868669